Skip to content

Clinical Observation of Duhuo Jisheng Decoction in the Treatment of Knee Osteoarthritis and Its Inhibition of Fibroblast-Like Synoviocyte Aggressive Behavior via the PGAM1-Glycolysis Pathway

Clinical Observation of Duhuo Jisheng Decoction in the Treatment of Knee Osteoarthritis and Its Inhibition of Fibroblast-Like Synoviocyte Aggressive Behavior via the PGAM1-Glycolysis Pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112662
Enrollment
Unknown
Registered
2025-11-18
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Control group:Intra-articular injection of sodium hyaluronate
Observation group:Based on the control group,the Duhuo Jisheng Decoction was administered orally for treatment

Sponsors

Shaoxing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meets the clinical diagnostic criteria for KOA and has signed the informed consent forms for treatment and follow-up; 2. No obvious skin damage, rash, or infection around the knee joint; 3. Has not taken similar drugs related to the study in the past year; 4. No obvious knee joint deformity.

Exclusion criteria

Exclusion criteria: 1. Patients who also have knee fractures, dislocations, trauma, or other injuries; 2. Patients who also have severe neurological diseases, cardiovascular diseases, kidney diseases, tumors, or other internal medical conditions; 3. Patients with severe knee osteoarthritis, significant knee deformity, and Kellgren-Lawrence (K-L) grade IV; 4. Patients with poor compliance who fail to take medication or follow treatment on time; 5. Patients diagnosed through laboratory and imaging exams with gouty arthritis, ankylosing spondylitis, or other types of osteoarthritis; 6. Patients with cognitive dysfunction.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale;The Western Ontario and MuMaster Universities Osteoarthritis Index;Glucose;Lactic acid;Matrix metalloproteinase-2;Matrix metalloproteinase-9;Clinical Response Rate;

Secondary

MeasureTime frame
Pyruvate kinase M2;Phosphoglycerate mutase 1;Hexokinase 2;Adverse Reaction Rate;

Countries

China

Contacts

Public ContactLi Guohua

Shaoxing Hospital of Traditional Chinese Medicine

liguohua202310@163.com+86 136 7579 5191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026